Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna, Inc. (MRNA) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
05:39pm, Friday, 15'th Nov 2024
Moderna, Inc. (NASDAQ:MRNA ) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 10:00 AM ET Company Participants Stephen Hoge - President Conference Call Participants Evan Wang
The Score: Spirit, Tesla, Moderna and More Stocks That Defined the Week
05:34pm, Friday, 15'th Nov 2024
Here are some of the major companies whose stocks moved on the week's news.
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
02:31pm, Friday, 15'th Nov 2024
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Hu
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
12:55pm, Friday, 15'th Nov 2024
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme
Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head
06:06pm, Thursday, 14'th Nov 2024
Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select va
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
04:40pm, Thursday, 14'th Nov 2024
Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.
Moderna, Inc. (MRNA) UBS Global Healthcare Conference (Transcript)
10:16pm, Wednesday, 13'th Nov 2024
Moderna, Inc. (NASDAQ:MRNA ) UBS Global Healthcare Conference November 13, 2024 6:30 PM ET Company Participants Jamey Mock - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Eli
Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers
01:30pm, Tuesday, 12'th Nov 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--CRDMO capabilities are tailored for a full range of mRNA applications, including small-scale quantities for personalized cancer vaccines (PCVs).
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet needle-free technology enhances mRNA vaccine immune response and has been successfully adopted into multiple vaccine development programs.
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
08:15am, Tuesday, 12'th Nov 2024
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Comp
mRNA Synthesis & Manufacturing Market - Global Forecast to 2029
11:08am, Monday, 11'th Nov 2024
Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
01:47pm, Friday, 08'th Nov 2024
On Thursday, Moderna Inc. MRNA reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion.
Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
10:36am, Friday, 08'th Nov 2024
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Str
2 Biotech Stocks You Can Buy Hand Over Fist This Month
10:00am, Friday, 08'th Nov 2024
Both stocks have made significant breakthroughs.
Canada approves Moderna's RSV vaccine for adults aged 60 and older
08:23am, Friday, 08'th Nov 2024
Moderna has received approval from Canada's health regulator for its respiratory syncytial virus vaccine in adults 60 years of age and older, the vaccine maker said on Friday.
